Health TrialsbyHealthPanel

Improving Access to Care for Veterans With Memory Loss

ConditionAlzheimer Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorVA Pittsburgh Healthcare System

About this trial

This study evaluates a care delivery protocol to improve access to care for Veterans with Alzheimer's Disease and Related Disorders (ADRD). A randomized controlled trial will enroll Veterans with mild cognitive impairment or early dementia at VA Pittsburgh. The ADRD care delivery protocol integrates telehealth, advanced diagnostics, and streamlined workflows to expedite screening for eligibility for amyloid targeting therapies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of mild cognitive impairment or mild dementia due to suspected or confirmed AD with a 5 minute telephone MoCA score >7

Meets VA MUE inclusion/

Disqualifiers

Enrolled in VA care

Lives in a home setting (i.e., not in an institutional setting such as a nursing home, Community Living Center, or hospital)

Has a working telephone

18 years and older

Trial design

Design model

Single group

Treatments tested in this trial

  • ADRD Care Delivery Protocol

    Other intervention

    1\. Included in arm/group descriptions

Treatment groups

30 Participants
are divided into 2 treatment groups
Group A: ADRD Care Delivery ProtocolExperimental treatment 1 intervention
Group B: Usual CareNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Time to Eligibility Determination

Compare the number of days from randomization to the determination of eligibility for monoclonal antibody therapy for both the intervention and usual care groups, assessed up to 12 months.

Time frame
From date of randomization until the date of determination of eligibility for monoclonal antibody therapy, assessed up to 12 months.
2

Time to Initial Infusion

Compare the number of days from the date of randomization to the initial infusion of monoclonal antibody therapy for both the intervention and usual care groups, assessed up to 12 months.

Time frame
From date of randomization until the date of first infusion, assessed up to 12 months.

Secondary outcomes

1

Number of Participants and Instances of Additional testing

Chart review will be used to determine the number of participants who underwent additional testing and the total number of additional tests performed. This includes counting instances of APOE genetic testing, MRI brain imaging, and amyloid PET imaging as ordered at the discretion of the specialist.

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

VA Pittsburgh Healthcare System

Lead sponsor

Source ClinicalTrials.gov
Apply now